Samsung Biologics, South Korea’s preeminent contract development and manufacturing organisation (CDMO), has entered into a momentous W1.8 trillion (USD 1.29 billion) agreement with an undisclosed US pharmaceutical firm, extending through to the close of 2029.

This significant contract elevates Samsung Biologics’ total value of manufacturing agreements for the year to over USD 3.6 billion, reinforcing its reputation as a global powerhouse in biopharmaceutical production.

In response to evolving client needs across Asia, Europe, and North America, Samsung Biologics has deftly secured substantial deals around the world, with collaborations now encompassing 17 of the top 20 pharmaceutical companies globally.

The company’s unparalleled operational capacity is anchored in its five state-of-the-art biopharmaceutical facilities in Songdo, Incheon, which collectively boast an annual production capability of 784,000 litres. This capacity is poised to rise sharply—to 1.324 million litres—through the phased addition of three new facilities by 2032.

Financially, Samsung Biologics continues to demonstrate resilience and growth: first-half operating profit leapt 47 percent year-on-year to reach KRW 962.3 billion, driven by healthy revenue of KRW 2.59 trillion. These results reflect both robust strategic execution and the full utilisation of existing facilities.

As Samsung Biologics extends its global reach and scale, this latest partnership further confirms its strategic vision: to lead the future of biopharmaceutical manufacturing, powered by innovation, capacity expansion, and unwavering client commitment.